CKD Bio Corp
063160
Company Profile
Business description
CKD Bio Corp is engaged in producing high-quality raw pharmaceutical ingredients, such as antibiotics and immunosuppressants, and supply them to domestic and international pharmaceutical companies. The company also purchases finished pharmaceutical products from domestic and international markets for export and domestic supply.
Contact
8 Chungjeong-ro, 3-ga Chungjeong-ro
Seodaemun-gu
Seoul
KORT: +82 221940555
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
530
Stocks News & Analysis
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.
stocks
ASX energy share remains cheap despite strong outlook
Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.
stocks
Moated AI-proof tech play hiding in the ASX 100
ChatGPT and large language models should be a tailwind for this company.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,006.40 | 19.00 | -0.21% |
| CAC 40 | 8,135.57 | 91.75 | -1.12% |
| DAX 40 | 24,054.82 | 100.63 | -0.42% |
| Dow JONES (US) | 49,310.32 | 179.71 | -0.36% |
| FTSE 100 | 10,387.96 | 69.05 | -0.66% |
| HKSE | 25,978.07 | 62.87 | 0.24% |
| NASDAQ | 24,438.50 | 219.06 | -0.89% |
| Nikkei 225 | 59,716.18 | 575.95 | 0.97% |
| NZX 50 Index | 12,874.94 | 9.99 | -0.08% |
| S&P 500 | 7,108.40 | 29.50 | -0.41% |
| S&P/ASX 200 | 8,786.50 | 12.10 | -0.14% |
| SSE Composite Index | 4,079.90 | 13.35 | -0.33% |